Alcoholic Hepatitis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Alcoholic Hepatitis – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alcoholic Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alcoholic Hepatitis: Overview
Alcoholic hepatitis is a diseased, inflammatory condition of the liver caused by heavy alcohol consumption over an extended period of time. It’s also aggravated by binge drinking and ongoing alcohol use. When alcohol gets processed in the liver, it produces highly toxic chemicals. These chemicals can injure the liver cells. This injury then leads to inflammation, and alcoholic hepatitis. Over time, scars begin to replace functional liver tissue in the body. This interferes with how the liver works. Irreversible scarring — or cirrhosis — is the final stage of alcoholic liver disease. Because alcoholic hepatitis doesn’t occur in all people who excessively use alcohol, other factors may influence the development of this condition. These include: genetic factors that affect how the body processes alcohol, the presence of liver infections or other liver disorders, such as hepatitis B, hepatitis C, and hemochromatosis, malnutrition, and being overweight. One of the most common signs of alcoholic hepatitis is jaundice, or yellowing of the skin and eyes. Additional symptoms include: loss of appetite, nausea, vomiting, stomach pain, fever, tiredness, and weakness. Blood tests to determine alcoholic hepatitis include: liver function studies, cellular blood counts, measuring bleeding times, electrolyte tests, and tests for other chemicals in the body. The main treatment for alcoholic hepatitis is to stop consuming alcohol. There is no cure for alcoholic hepatitis, but treatment will aim to reduce or eliminate symptoms and stop the progression of the disease.
'Alcoholic Hepatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alcoholic Hepatitis pipeline landscape is provided which includes the disease overview and Alcoholic Hepatitis treatment guidelines. The assessment part of the report embraces, in depth Alcoholic Hepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alcoholic Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Alcoholic Hepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alcoholic Hepatitis Emerging Drugs
Further product details are provided in the report……..
Alcoholic Hepatitis: Therapeutic Assessment
This segment of the report provides insights about the different Alcoholic Hepatitis drugs segregated based on following parameters that define the scope of the report, such as:
Alcoholic Hepatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alcoholic Hepatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alcoholic Hepatitis drugs.
Alcoholic Hepatitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Alcoholic Hepatitis – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alcoholic Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Alcoholic Hepatitis: Overview
Alcoholic hepatitis is a diseased, inflammatory condition of the liver caused by heavy alcohol consumption over an extended period of time. It’s also aggravated by binge drinking and ongoing alcohol use. When alcohol gets processed in the liver, it produces highly toxic chemicals. These chemicals can injure the liver cells. This injury then leads to inflammation, and alcoholic hepatitis. Over time, scars begin to replace functional liver tissue in the body. This interferes with how the liver works. Irreversible scarring — or cirrhosis — is the final stage of alcoholic liver disease. Because alcoholic hepatitis doesn’t occur in all people who excessively use alcohol, other factors may influence the development of this condition. These include: genetic factors that affect how the body processes alcohol, the presence of liver infections or other liver disorders, such as hepatitis B, hepatitis C, and hemochromatosis, malnutrition, and being overweight. One of the most common signs of alcoholic hepatitis is jaundice, or yellowing of the skin and eyes. Additional symptoms include: loss of appetite, nausea, vomiting, stomach pain, fever, tiredness, and weakness. Blood tests to determine alcoholic hepatitis include: liver function studies, cellular blood counts, measuring bleeding times, electrolyte tests, and tests for other chemicals in the body. The main treatment for alcoholic hepatitis is to stop consuming alcohol. There is no cure for alcoholic hepatitis, but treatment will aim to reduce or eliminate symptoms and stop the progression of the disease.
'Alcoholic Hepatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alcoholic Hepatitis pipeline landscape is provided which includes the disease overview and Alcoholic Hepatitis treatment guidelines. The assessment part of the report embraces, in depth Alcoholic Hepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alcoholic Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alcoholic Hepatitis R&D. The therapies under development are focused on novel approaches to treat/improve Alcoholic Hepatitis.
This segment of the Alcoholic Hepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alcoholic Hepatitis Emerging Drugs
- DUR-928: Durect
- Canakinumab: Novartis
Further product details are provided in the report……..
Alcoholic Hepatitis: Therapeutic Assessment
This segment of the report provides insights about the different Alcoholic Hepatitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alcoholic Hepatitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Alcoholic Hepatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alcoholic Hepatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alcoholic Hepatitis drugs.
Alcoholic Hepatitis Report Insights
- Alcoholic Hepatitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alcoholic Hepatitis drugs?
- How many Alcoholic Hepatitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alcoholic Hepatitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alcoholic Hepatitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alcoholic Hepatitis and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Alcoholic Hepatitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DUR-928: Durect
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
SRT-015: Seal Rock therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alcoholic Hepatitis Key Companies
Alcoholic Hepatitis Key Products
Alcoholic Hepatitis- Unmet Needs
Alcoholic Hepatitis- Market Drivers and Barriers
Alcoholic Hepatitis- Future Perspectives and Conclusion
Alcoholic Hepatitis Analyst Views
Alcoholic Hepatitis Key Companies
Appendix
Executive Summary
Alcoholic Hepatitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DUR-928: Durect
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
SRT-015: Seal Rock therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alcoholic Hepatitis Key Companies
Alcoholic Hepatitis Key Products
Alcoholic Hepatitis- Unmet Needs
Alcoholic Hepatitis- Market Drivers and Barriers
Alcoholic Hepatitis- Future Perspectives and Conclusion
Alcoholic Hepatitis Analyst Views
Alcoholic Hepatitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Alcoholic Hepatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Alcoholic Hepatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Alcoholic Hepatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Alcoholic Hepatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
